Altamira Therapeutics Ltd. (CYTO)

NASDAQ: CYTO · IEX Real-Time Price · USD

1.200

-0.140 (-10.45%)

At close: Jul 19, 2024, 4:00 PM

1.170

-0.030 (-2.50%)

Pre-market: Jul 22, 2024, 7:22 AM EDT

Altamira Therapeutics Income Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2012
Selling, General & Admin	3.14	3.14	3.4	3.67	2.59	3.93	Upgrade
Research & Development	3.04	3.04	14.62	3.2	2.86	3.33	Upgrade
Other Operating Expenses	-0.26	-0.26	-0.01	0	0.05	0	Upgrade
Operating Expenses	5.92	5.92	18.01	6.87	5.5	7.26	Upgrade
Operating Income	-5.92	-5.92	-18.01	-6.87	-5.5	-7.26	Upgrade
Interest Expense / Income	1.67	1.67	1.21	0.01	0.14	0.03	Upgrade
Other Expense / Income	-3.72	-3.72	7.31	10.29	2.58	-0.46	Upgrade
Pretax Income	-3.87	-3.87	-26.54	-17.18	-8.22	-6.83	Upgrade
Income Tax	0	0	-0.01	-0.12	-0.02	-0.19	Upgrade
Net Income	-3.87	-3.87	-26.53	-17.06	-8.2	-6.63	Upgrade
Shares Outstanding (Basic)	0	0	0	0	0	0	Upgrade
Shares Change	1066.00%	832.23%	25.08%	169.67%	169.85%	674.71%	Upgrade
EPS (Basic)	-7.88	-7.88	-582.58	-515.11	-505.40	-45.60	Upgrade
EPS (Diluted)	-7.88	-7.88	-582.58	-515.11	-505.40	-45.60	Upgrade
Free Cash Flow	-11.51	-11.51	-8.68	-13.67	-4.84	-8.46	Upgrade
Free Cash Flow Per Share	-28.94	-28.94	-203.54	-400.87	-382.95	-1804.37	Upgrade
EBITDA	-2.08	-2.08	-25.21	-17.09	-8.07	-6.77	Upgrade
Depreciation & Amortization	0.12	0.12	0.12	0.08	0.02	0.03	Upgrade
EBIT	-2.2	-2.2	-25.33	-17.16	-8.09	-6.8	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).